The synthesis of N-benzoylindoles as inhibitors of rat erythrocyte glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase

Figure S1. ¹H NMR (400 MHz) spectra of 1-(2-nitro-1-phenylethyl) indoline (7a)

Figure S2. ¹³C NMR (100 MHz) spectra of 1-(2-nitro-1-phenylethyl)indoline (7a)

Figure S3. ¹H NMR (400 MHz) spectra of 1-(2-nitro-1-phenylethyl)-1H-indole (8a)

Figure S4. APT ¹³C NMR (100 MHz) spectra of 1-(2-nitro-1-phenylethyl)-1H-indole (8a)

Figure S5. ¹H NMR (400 MHz) spectra of 1-(2-nitro-1-(2-nitrophenyl) ethyl) indoline (7e)

Figure S6. APT ¹³C NMR (100 MHz) spectra of 1-(2-nitro-1-(2-nitrophenyl)ethyl)indoline (7e)

Figure S7. ¹H NMR (400 MHz) spectra of 1-(1-(4-chlorophenyl)-2-nitroethyl)-1H-indole (8b)

Figure S8. ¹³C NMR (100 MHz) spectra of 1-(1-(4-chlorophenyl)-2-nitroethyl)-1H-indole (8b)

Figure S9. ¹H NMR (400 MHz) spectra of 1-(1-(furan-2-yl)-2-nitroethyl)-1H-indole (8c)

Figure S10. ¹³C NMR (100 MHz) spectra of 1-(1-(furan-2-yl)-2-nitroethyl)-1H-indole (8c)

Figure S11. ¹H NMR (400 MHz) spectra of 1-(2-nitro-1-(thiophen-2-yl)ethyl)-1H-indole (8d)

Figure S12. ¹³C NMR (100 MHz) spectra of 1-(2-nitro-1-(thiophen-2-yl)ethyl)-1H-indole (8d)

Figure S13. ¹H NMR (400 MHz) spectra of (1H-indol-1-yl)(phenyl)methanone (9a)

Figure S14. ¹³C NMR (100 MHz) spectra of (1H-indol-1-yl)(phenyl)methanone (9a)

Figure S15. ¹H NMR (400 MHz) spectra of (4-chlorophenyl)(1H-indol-1-yl)methanone (9b)

Figure S16. APT ¹³C NMR (100 MHz) spectra of (4-chlorophenyl)(1H-indol-1-yl)methanone (9b)

Figure S17. ¹H NMR (400 MHz) spectra of furan-2-yl(1H-indol-1-yl)methanone (9c)

Figure S18. APT ¹³C NMR (100 MHz) spectra of furan-2-yl(1H-indol-1-yl)methanone (9c)

Figure S19. ¹H NMR (400 MHz) spectra of (1H-indol-1-yl)(thiophen-2-yl)methanone (9d)

Figure S20. APT ¹³C NMR (100 MHz) spectra of (1H-indol-1-yl)(thiophen-2-yl)methanone (9d)

Figure S21. In vitro effect of 8a (a), 8b (b), and 8c (c) on rat erythrocyte G6PD with corresponding IC₅₀ graphs.

Figure S22. a) In vitro effect of 8d on rat erythrocyte G6PD with corresponding IC₅₀ graph and b) Lineweaver–Burk double reciprocal plot of initial velocity against G6PD and inhibitor 8d at different concentrations.

Figure S23. a) In vitro effect of 9a on rat erythrocyte G6PD with corresponding IC₅₀ graph and b) Lineweaver–Burk double reciprocal plot of initial velocity against G6PD and inhibitor 9a at different concentrations

Figure S24. a) In vitro effect of 9b on rat erythrocyte G6PD with corresponding IC₅₀ graph and b) Lineweaver–Burk double reciprocal plot of initial velocity against G6PD and inhibitor 9b at different concentrations.

Figure S25. a) In vitro effect of 9c on rat erythrocyte G6PD with corresponding IC₅₀ graph and b) Lineweaver–Burk double reciprocal plot of initial velocity against G6PD and inhibitor 9c at different concentrations.

Figure S26. a) In vitro effect of 9d on rat erythrocyte G6PD with corresponding IC₅₀ graph and b) Lineweaver–Burk double reciprocal plot of initial velocity against G6PD and inhibitor 9d at different concentrations.

Figure S27. In vitro effect of 8a (a), 8b (b), and 8c (c) on rat erythrocyte 6PGD with corresponding IC₅₀ graphs.

Figure S28. In vitro effect of 8d (a), 9a (b), and 9b (c) on rat erythrocyte 6PGD with corresponding IC₅₀ graphs.

Figure S29. In vitro effect of 9c (a), and 9d (b) on rat erythrocyte 6PGD with corresponding IC₅₀ graphs

Figure S30. ¹H NMR (400 MHz) spectra of (E or Z) 1-(2-nitro-1-phenylvinyl)-1H-indole (11) and 9a, obtained the 6PGD-catalyst reaction of 1-(2-nitro-1-phenylethyl)-1H-indole (8a) with NADP.